STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Clinical trials for STAGE IIIC CUTANEOUS MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIC CUTANEOUS MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIC CUTANEOUS MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 23:20 UTC
-
Engineered immune cells take on deadly skin cancer
Disease control OngoingThis early-phase study tests whether giving patients with advanced melanoma their own genetically modified T-cells, followed by high-dose interleukin-2, is safe and feasible. The T-cells are altered in the lab to resist a protein that normally stops them from attacking tumors. Ab…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New combo therapy shows promise for melanoma patients who failed previous treatment
Disease control OngoingThis study tests a combination of two drugs—T-VEC, a virus-based therapy that attacks tumors, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in people with advanced melanoma that has worsened after prior treatment. About 43 participants with stage I…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Triple threat: new drug cocktail takes on tough melanoma
Disease control OngoingThis study tests whether combining an immunotherapy drug (nivolumab) with two targeted drugs (either dabrafenib + trametinib or encorafenib + binimetinib) can shrink or control advanced melanoma that has spread to the brain or other organs. About 52 adults with a specific gene mu…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Double immune attack: new combo therapy shows promise for tough melanoma
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Experimental combo aims to starve cancer cells in Late-Stage tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Can a drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either the combination or ipilimumab alone. The main goal was to see if the …
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:09 UTC
-
Major trial tests immune drug against standard therapy for High-Risk melanoma
Disease control OngoingThis large phase 3 study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. Over 1,600 patients with high-risk stage III or IV melanoma that had been completely removed took part. …
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Drug combo shrinks melanoma tumors before surgery, study shows
Disease control OngoingThis study tested two targeted drugs, dabrafenib and trametinib, given before and after surgery in 58 people with stage III melanoma that has a BRAF gene mutation. The goal was to shrink tumors before surgery and kill any remaining cancer cells afterward. The approach aims to imp…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
Two-Drug cocktail shows promise for Tough-to-Treat melanoma
Disease control OngoingThis early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes cancer cells need to grow)—in people with advanced melanoma that cannot be removed by surgery. The main g…
Matched conditions: STAGE IIIC CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC